Vector began testing the effectiveness of the third dose of EpiVacCorona

The Vector Novosibirsk Center for Virology and Biotechnology is testing the possibility of triple administration of the EpiVacCorona CORONAVIRUS vaccine to enhance the effect of antibodies. This was announced by the HEAD of the department of zoonotic infections of the center, Alexander Ryzhikov, on the air of the official account of Rospotrebnadzor of the Russian Federation on Instagram.

“We tested the triple vaccination on animals. The effect of the increase and duration of immunity has been confirmed, now phase 1-2 clinical trials are underway for the introduction of a triple vaccination with this vaccine, ”said Ryzhikov.

According to him, the introduction of the third dose of the EpiVacCoron vaccine will not only increase the level of neutralizing antibodies, but also ensure a high level of interaction between these antibodies. Ryzhikov added that this drug, due to its harmlessness, is suitable for double revaccination.

“We will achieve a sufficient immune response, including among the elderly,” Ryzhikov said.

As Vector reported, after vaccination with EpiVacCorona, antibodies are produced that neutralize the classic, British and South African strains of coronavirus.

Read together with it: